VENUS®
Enjoy Innovations

VRL/SEC/EXCHANGE 13.11.15

National Stock Exchange of India Ltd. 5th Floor , Exchange Plaza Bandra (E), Mumbai- 400 051	**Dept. of Corporate Services** The Stock Exchange, Mumbai 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai

Sub.: Outcome of Board Meeting

Dear Sir,

This is to inform you that, the Board of Directors of the Company at its meeting held today considered and approved the Unaudited Financial Results (Provisional) for the quarter ended 30.09.2015. Agenda item to reconsider the relevant date for preferential issue could not be discussed due to some approvals pending from exchanges.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED.

Neha Kodan
(Company Secretary)

VENUS REMEDIES LIMITED
Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

EZENUS™
Brings balance to life
Stress Reliever Herbal Candy

Stress Reliever with Liver Detoxifier & Antioxidant Property

Low Calorie Candy
A German Technology

VENUS®
Enjoy Innovations

VRL/SEC/EXCHANGE

13.11.15

National Stock Exchange of India Ltd. 5th Floor , Exchange Plaza Bandra (E), Mumbai- 400 051	**Dept. of Corporate Services** The Stock Exchange, Mumbai 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai

Sub: Submission of Unaudited Financial results as on 30.09.2015

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results (provisional) along with limited review report for the quarter ended on 30.09.2015 which were taken on record by the Board of Directors at its meeting held on 13.11.2015

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED.

Neha Kodan
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

MOODY INTERNATIONAL
UKAS QUALITY MANAGEMENT
UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

EZENUS™
Brings balance to life
Stress Reliever Herbal Candy

Stress Reliever with Liver Detoxifier & Antioxidant Property

Low Calorie Candy
A German Technology

VENUS®
Enjoy Innovations

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)

FOR THE QUARTER ENDED 30TH SEPTEMBER, 2015 (Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on			Half Year Ended on		Year Ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
	Part – I	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Net Sales/ Income from operations**						
	Gross Sales	1010.02	987.11	1254.85	1997.13	2465.4	4504.05
	Less : Excise Duty	1.36	1.92	1.1	3.28	3.52	6.6
	(a) Net Sales	1008.66	985.19	1253.75	1993.85	2461.88	4497.45
	(b) Other Operating Income	50.78	3.93	5.76	54.71	12.42	21.3
	Total Income from Operation (Net)	**1,059.44**	**989.12**	**1,259.51**	**2,048.56**	**2,474.30**	**4,518.75**
2	**Expenses**						
	(a) Consumption of raw materials	654.64	590.01	783.75	1244.65	1413.17	2,643.89
	(b) (Increase)/ Decrease in stock in trade	-7.58	5.55	1.31	-2.03	50.43	65.28
	(c) Employee benefits expense	61.51	61.82	68.99	123.33	132.41	272.55
	(d) Depreciation & amortisation expense	101.06	99.60	82.29	200.66	193.59	447.41
	(e) Other expenses	147.58	139.80	138.24	287.38	314.69	667.70
	Total expense	**957.21**	**896.78**	**1,074.58**	**1,853.99**	**2,104.29**	**4,096.83**
3	**Profit from operations before other income , finance costs and exceptional items (1-2)**	**102.23**	**92.34**	**184.93**	**194.57**	**370.01**	**421.92**
	EBIDTA (3+2(D)	**203.3**	**191.94**	**267.2**	**395.2**	**563.6**	**869.33**
4	Other income	1.19	1.04	1.12	2.23	2.12	5.46
5	**Profit before finance costs and exceptional items (3+4)**	**103.42**	**93.38**	**186.05**	**196.80**	**372.13**	**427.38**
6	Finance Costs	87.37	91.45	83.01	178.82	166.60	407.03
7	**Profit after finance costs but before exceptional items (5-6)**	**16.05**	**01.93**	**103.04**	**17.98**	**205.53**	**20.35**
8	Exceptional items	0.00	0.00	0.00	0	0	00.00
9	**Profit from ordinary activities before tax (7+8)**	**16.05**	**01.93**	**103.04**	**17.98**	**205.53**	**20.35**
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00	-25.13
11	**Profit from ordinary activities after tax (9-10)**	**16.05**	**01.93**	**103.04**	**17.98**	**205.53**	**45.48**
12	Exceptional items	00.00	00.00	00.00	0.00	0.00	0.00
13	**Net profit for the period (11-12)**	**16.05**	**01.93**	**103.04**	**17.98**	**205.53**	**45.48**
14	**Paid up Equity Share Capital**	**114.42**	**114.42**	**114.42**	**114.42**	**114.42**	**114.42**
15	**Reserves excluding revaluation reserves**	**N. A.**	**N. A.**	**N. A.**	**N. A.**	**N. A.**	**4,547.93**
16	**E.P.S - Basic not annualised for the qtr**	**1.40**	**0.17**	**9.01**	**1.57**	**17.96**	**3.97**
	- Annualised	**5.61**	**0.67**	**36.02**	**3.14**	**35.93**	**3.97**
	Part-II (A) PARTICULARS OF SHAREHOLDING						
1)	**Public Shareholding**						
	- Number of Shares	7711988	7711988	7520988	7520988	7520988	7711988
	- Percentage of Shareholding	67.40	67.40	65.73	65.73	65.73	67.40
2	**Promoters and promoter group shareholding**						
	a) Pledged as collateral security to bank						
	- Number of Shares	3630000	3630000	1621000	1621000	1621000	3730000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	97.32	97.32	41.34	41.34	41.34	100.00
	- Percentage of shares (as a % of the total share capital	31.73	31.73	14.17	14.17	14.17	32.60
	b) Non-Encumbered						
	- Number of Shares	100000	100000	2300000	2300000	2300000	0 0
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	02.68	02.68	58.66	58.66	58.66	00 0
	- Percentage of shares (as a % of the total share capital	00.87	00.87	20.10	20.10	20.10	00.00

Particulars	Quarter ended 30.09.2015
(B) INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	0
Disposed of during the quarter	0
Remaining unresolved at the end of the quarter	NIL

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

VENUS®
Enjoy Innovations

Standalone Statement of Assets and Liabilities

	Particulars	Half Year Ended on 30/09/2015	Year Ended on 31/03/2015
A	**EQUITY AND LIABILITIES**	(` In Millions)	(` In Millions)
1	**Shareholders' funds**		
	(a) Share capital	114.42	114.42
	(b) Reserves and surplus	4565.91	4547.93
	Sub-total – Shareholders' funds	4680.33	4662.35
2	**Non-current liabilities**		
	(a) Long-term borrowings	1726.86	1685.6
	(b) Deferred tax liabilities (net)	147.78	147.78
	(c) Other long-term liabilities	6.85	6.91
	(d) Long-term provisions	40.73	37.84
	Sub-total – Non-current liabilities	1922.22	1878.13
3	**Current liabilities**		
	(a) Short-term borrowings	1153.82	1153.99
	(b) Trade payables	224.22	257.62
	(c) Other current liabilities	496.99	476.83
	(d) Short-term provisions	4.03	19.08
	Sub-total – Current liabilities	1879.06	1907.52
	TOTAL – EQUITY AND LIABILITIES	8481.61	8448.00
B	**ASSETS**		
1	**Non-current assets**		
	(a) Fixed assets	5128.08	5040.68
	(b) Non-current investments	287.36	287.36
	(c) Long-term loans and advances	520.67	516.53
	Sub-total – Non-current assets	5936.11	5844.57
2	**Current assets**		
	(a) Current investments		
	(b) Inventories	1396.69	1404.38
	(c) Trade receivables	574.55	593.7
	(d) Cash and cash equivalents	31.63	35.21
	(e) Short-term loans and advances	542.63	570.14
	Sub-total – Current assets	2545.5	2603.43
	TOTAL – ASSETS	8481.61	8448.00

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

VENUS®
Enjoy Innovations

Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on November 13, 2015.

2. Investor Complaints pending during the beginning of the quarter-NIL, Received during the quarter-NIL, Disposed of during the quarter-NIL, Remaining unresolved at the end of the quarter-NIL.

3. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

Pawan Chaudhary
(Managing Director)

Date : 13.11.2015

J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022
0172-270 4536-37 Fax : 0172-270 4537
E-mail : jkjcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of Venus **Remedies Limited** for the Half year/ Quarter ended 30.09.2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Half yearly/ Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,
(Chartered Accountants)

J K Jain

(J.KJain)
Partner
M.No. 083140
FRN No. 004025N

Date : 13.11.2015
Place : Chandigarh